VKTX — Viking Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1607678 ·
Last close
$26.88
Market Cap
$3.43B
52W High
$43.10
52W Low
$23.82
ADV30
4,606,357
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -132,597,000 -128,022,000 521,898,000 125,750,000 113,581,000
Mar 2026 0 — -164,125,000 -158,325,000 608,242,000 118,116,000 106,325,000
Dec 2025 0 — -164,738,000 -157,662,000 715,729,000 165,810,000 76,667,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-462,632,000
Investing CF
$331,751,000
Financing CF
$708,317,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.40
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,317,079,000
Inventory
—
Receivables
—
ST Investments
$282,204,000
EBIT TTM
$-644,558,000
Pretax Income TTM
$-627,195,000
Interest Exp TTM
$88,000
Analysts
19

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -393,342,000 -359,639,000 715,729,000 76,667,000 639,062,000 -278,685,000
Dec 2024 0 -150,921,000 -109,963,000 908,321,000 28,043,000 880,278,000 -87,790,000
Dec 2023 0 -100,827,000 -85,895,000 368,490,000 20,071,000 348,419,000 -73,376,000
Dec 2022 0 -70,355,000 -68,867,000 168,529,000 23,207,000 145,322,000 -48,397,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-534,796,000
OpCashFlow TTM
—
Assets (Latest)
$521,898,000
Forward EPS
$-5.08

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $27.50 · spot: $26.17 · call volume: 320 · put volume: 1,391
Expected Move to 2026-12-18: ±$5.11 (19.53%) — implied range $21.06 – $31.28 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VRDN Viridian Therapeutics, Inc.\DE $3.41B $30.06 —
ELVN Enliven Therapeutics, Inc. $3.45B $46.85 —
ARQT Arcutis Biotherapeutics, Inc. $3.46B $27.33 —
IRON Disc Medicine, Inc. $3.49B $76.57 —
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —

News headlines (Yahoo Finance, 1h cache)

Learn Why The Bull Case For Viking Therapeutics Stock Could Change Following Obesity Drug Trial Progress
2026-11-18 21:09 · Yahoo
Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing
2026-11-18 18:14 · Yahoo
Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.
2026-11-18 13:20 · Yahoo
Viking: 3 Key Takeaways for Long-Term Investors
2026-11-17 05:29 · Yahoo
Should You Trim Or Add To Your Viking Therapeutics Position?
2026-11-16 19:46 · Yahoo
Viking's Obesity Drug in Competitive Position Ahead of Phase 3 Readout, Oppenheimer Says
2026-11-16 18:55 · Yahoo
VKTX Stock Gives Back Buyout Speculation-Spurred Gains, Investors Continue To Await Key Obesity Trial Topline Data
2026-11-16 18:50 · Yahoo
Why Did Viking Therapeutics Stock Jump?
2026-11-16 11:42 · Yahoo
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
2026-11-15 17:05 · Yahoo
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
2026-11-13 09:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.